Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes

  • Sevilla, Julián|||0000-0002-6852-1860
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Río, Paula
  • Sánchez Domínguez, Rebeca
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Gálvez, Eva
  • Merino, Eva
  • Sebastián, Elena
  • Azqueta, Carmen
  • Casado, José A.|||0000-0003-2479-1508
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Román-Rodríguez, Francisco J.
  • Giménez, Yari|||0000-0002-8936-0007
  • Larcher, Lise
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hladun, Raquel|||0000-0002-3191-1750
  • Castillo, Ana
  • Soulier, Jean|||0000-0002-8734-5356
  • Querol, Sergi|||0000-0002-1105-8633
  • Fernández, Jesús
  • Schwartz, Jonathan|||0000-0002-2211-4151
  • García de Andoín, Nagore|||0000-0003-2660-2600
  • López, Ricardo
  • Català, Albert|||0000-0003-0133-1752
  • Surralles, Jordi|||0000-0002-4041-7519
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Bueren, Juan|||0000-0002-3228-7013
Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization of HSPCs and collection by leukapheresis in FA patients. Nine of eleven enrolled patients mobilized beyond the threshold level of 5 CD34 + cells/μL required to initiate apheresis. A median of 21.8 CD34 + cells/μL was reached at the peak of mobilization. Significantly, the oldest patients (15 and 16 years old) were the only ones who did not reach that threshold. A median of 4.27 million CD34 + cells/kg was collected in 2 or 3 aphereses. These numbers were markedly decreased to 1.1 million CD34 + cells/kg after immunoselection, probably because of weak expression of the CD34 antigen. However, these numbers were sufficient to facilitate the engraftment of corrected HSPCs in non-conditioned patients. No procedure-associated serious adverse events were observed. Mobilization of CD34 + cells correlated with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher proportion of CD34 + cells in bone marrow (BM). All these values offer crucial information for the enrollment of FA patients for gene therapy protocols. Mobilization and collection of HSPCs from FA patients with sufficient HSPC reserve is a safe and efficient procedure, incorporating filgrastim and plerixafor as mobilization agents. Adequate HSPC mobilization correlates with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher BM CD34 + cell numbers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

TALEN mediated gene editing in a mouse model of Fanconi anemia

  • Pino-Barrio, Maria José
  • Giménez, Yari|||0000-0002-8936-0007
  • Villanueva, Mariela
  • Hildenbeutel, Marcus
  • Sánchez Domínguez, Rebeca
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Surralles, Jordi|||0000-0002-4041-7519
  • Río, Paula
  • Cathomen, Toni|||0000-0002-7757-4630
  • Mussolino, Claudio
  • Bueren, Juan|||0000-0002-3228-7013
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
The promising ability to genetically modify hematopoietic stem and progenitor cells by precise gene editing remains challenging due to their sensitivity to in vitro manipulations and poor efficiencies of homologous recombination. This study represents the first evidence of implementing a gene editing strategy in a murine safe harbor locus site that phenotypically corrects primary cells from a mouse model of Fanconi anemia A. By means of the co-delivery of transcription activator-like effector nucleases and a donor therapeutic FANCA template to the Mbs85 locus, we achieved efficient gene targeting (23%) in mFA-A fibroblasts. This resulted in the phenotypic correction of these cells, as revealed by the reduced sensitivity of these cells to mitomycin C. Moreover, robust evidence of targeted integration was observed in murine wild type and FA-A hematopoietic progenitor cells, reaching mean targeted integration values of 21% and 16% respectively, that were associated with the phenotypic correction of these cells. Overall, our results demonstrate the feasibility of implementing a therapeutic targeted integration strategy into the m Mbs85 locus, ortholog to the well-validated hAAVS1, constituting the first study of gene editing in mHSC with TALEN, that sets the basis for the use of a new safe harbor locus in mice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

  • Casado, José A.|||0000-0003-2479-1508
  • Valeri, A.
  • Sánchez Domínguez, Rebeca
  • Vela, Paula
  • Lopez, A.
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Hanenberg, H.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Segovia, J. C.
  • Minguillon, J.
  • Surralles, Jordi|||0000-0002-4041-7519
  • De Heredia, C.D.
  • Sevilla, J.
  • Rio, P.
  • Bueren, Juan|||0000-0002-3228-7013
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.